171 related articles for article (PubMed ID: 16436669)
1. Override of the osteoclast defect in osteopontin-deficient mice by metastatic tumor growth in the bone.
Natasha T; Kuhn M; Kelly O; Rittling SR
Am J Pathol; 2006 Feb; 168(2):551-61. PubMed ID: 16436669
[TBL] [Abstract][Full Text] [Related]
2. Novel murine mammary epithelial cell lines that form osteolytic bone metastases: effect of strain background on tumor homing.
Chen Y; Rittling SR
Clin Exp Metastasis; 2003; 20(2):111-20. PubMed ID: 12705632
[TBL] [Abstract][Full Text] [Related]
3. Osteoclasts resorb protein-free mineral (Osteologic discs) efficiently in the absence of osteopontin.
Contractor T; Babiarz B; Kowalski AJ; Rittling SR; Sørensen ES; Denhardt DT
In Vivo; 2005; 19(2):335-41. PubMed ID: 15796195
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.
Ishijima M; Rittling SR; Yamashita T; Tsuji K; Kurosawa H; Nifuji A; Denhardt DT; Noda M
J Exp Med; 2001 Feb; 193(3):399-404. PubMed ID: 11157060
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin is associated with nuclear factor kappaB gene expression during tail-suspension-induced bone loss.
Ishijima M; Ezura Y; Tsuji K; Rittling SR; Kurosawa H; Denhardt DT; Emi M; Nifuji A; Noda M
Exp Cell Res; 2006 Oct; 312(16):3075-83. PubMed ID: 16889770
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues.
Nemoto H; Rittling SR; Yoshitake H; Furuya K; Amagasa T; Tsuji K; Nifuji A; Denhardt DT; Noda M
J Bone Miner Res; 2001 Apr; 16(4):652-9. PubMed ID: 11315992
[TBL] [Abstract][Full Text] [Related]
7. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases.
Ibrahim T; Leong I; Sanchez-Sweatman O; Khokha R; Sodek J; Tenenbaum HC; Ganss B; Cheifetz S
Clin Exp Metastasis; 2000; 18(3):253-60. PubMed ID: 11315099
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption.
Yoshitake H; Rittling SR; Denhardt DT; Noda M
Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8156-60. PubMed ID: 10393964
[TBL] [Abstract][Full Text] [Related]
9. Molecular analysis of metastasis in a polyomavirus middle T mouse model: the role of osteopontin.
Jessen KA; Liu SY; Tepper CG; Karrim J; McGoldrick ET; Rosner A; Munn RJ; Young LJ; Borowsky AD; Cardiff RD; Gregg JP
Breast Cancer Res; 2004; 6(3):R157-69. PubMed ID: 15084239
[TBL] [Abstract][Full Text] [Related]
10. Impaired anti-tumor cytotoxicity of macrophages from osteopontin-deficient mice.
Bourassa B; Monaghan S; Rittling SR
Cell Immunol; 2004 Jan; 227(1):1-11. PubMed ID: 15051510
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin-deficiency suppresses growth of B16 melanoma cells implanted in bone and osteoclastogenesis in co-cultures.
Ohyama Y; Nemoto H; Rittling S; Tsuji K; Amagasa T; Denhardt DT; Nifuji A; Noda M
J Bone Miner Res; 2004 Oct; 19(10):1706-11. PubMed ID: 15355566
[TBL] [Abstract][Full Text] [Related]
12. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression.
Chellaiah MA; Kizer N; Biswas R; Alvarez U; Strauss-Schoenberger J; Rifas L; Rittling SR; Denhardt DT; Hruska KA
Mol Biol Cell; 2003 Jan; 14(1):173-89. PubMed ID: 12529435
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin deficiency suppresses high phosphate load-induced bone loss via specific modulation of osteoclasts.
Koyama Y; Rittling SR; Tsuji K; Hino K; Salincarnboriboon R; Yano T; Taketani Y; Nifuji A; Denhardt DT; Noda M
Endocrinology; 2006 Jun; 147(6):3040-9. PubMed ID: 16513836
[TBL] [Abstract][Full Text] [Related]
14. Osteopontin deficiency enhances anabolic action of EP4 agonist at a sub-optimal dose in bone.
Kato N; Kitahara K; Rittling SR; Nakashima K; Denhardt DT; Kurosawa H; Ezura Y; Noda M
J Endocrinol; 2007 Apr; 193(1):171-82. PubMed ID: 17400814
[TBL] [Abstract][Full Text] [Related]
15. Osteopontin as a positive regulator in the osteoclastogenesis of arthritis.
Ishii T; Ohshima S; Ishida T; Mima T; Tabunoki Y; Kobayashi H; Maeda M; Uede T; Liaw L; Kinoshita N; Kawase I; Saeki Y
Biochem Biophys Res Commun; 2004 Apr; 316(3):809-15. PubMed ID: 15033472
[TBL] [Abstract][Full Text] [Related]
16. Mice lacking bone sialoprotein (BSP) lose bone after ovariectomy and display skeletal site-specific response to intermittent PTH treatment.
Wade-Gueye NM; Boudiffa M; Laroche N; Vanden-Bossche A; Fournier C; Aubin JE; Vico L; Lafage-Proust MH; Malaval L
Endocrinology; 2010 Nov; 151(11):5103-13. PubMed ID: 20844009
[TBL] [Abstract][Full Text] [Related]
17. Proline/arginine-rich end leucine-rich repeat protein N-terminus is a novel osteoclast antagonist that counteracts bone loss.
Rucci N; Capulli M; Ventura L; Angelucci A; Peruzzi B; Tillgren V; Muraca M; Heinegård D; Teti A
J Bone Miner Res; 2013 Sep; 28(9):1912-24. PubMed ID: 23559035
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone.
Asou Y; Rittling SR; Yoshitake H; Tsuji K; Shinomiya K; Nifuji A; Denhardt DT; Noda M
Endocrinology; 2001 Mar; 142(3):1325-32. PubMed ID: 11181551
[TBL] [Abstract][Full Text] [Related]
19. Bone sialoprotein, but not osteopontin, deficiency impairs the mineralization of regenerating bone during cortical defect healing.
Monfoulet L; Malaval L; Aubin JE; Rittling SR; Gadeau AP; Fricain JC; Chassande O
Bone; 2010 Feb; 46(2):447-52. PubMed ID: 19761880
[TBL] [Abstract][Full Text] [Related]
20. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells.
Mi Z; Guo H; Wai PY; Gao C; Kuo PC
Carcinogenesis; 2006 Jun; 27(6):1134-45. PubMed ID: 16474180
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
